A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug ...

Discover comprehensive details about Nilotinib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug ...

December 14, 2009 — Nilotinib (Tasigna) demonstrated greater efficacy than imatinib (Gleevec) in adult patients with newly diagnosed Philadelphia-chromosome-positive chronic myeloid leukemia (CML) in ...

Adults with Ph+ CML in the CP or AP, who had imatinib resistance or intolerance and had also failed to respond to dasatinib therapy, received oral nilotinib at a starting dose of 400 mg twice daily on ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a ...

According to the Company, the product is expected to be available in the coming weeks through Biologics by McKesson and Limited Specialty Distribution. The Food and Drug Administration (FDA) has ...

Alzheimer’s disease is a progressive neurodegenerative disease that currently has no known cure. New treatments are being evaluated and research is ongoing to try and halt or reverse its progression.

Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may ...

Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed ...